ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 学会発表・講演等
  2. ポスター発表

Alpha-radioimmunotherapy with At211-trastuzumab against peritoneal metastasis of HER2-overexpressing gastric cancer.

https://repo.qst.go.jp/records/72144
https://repo.qst.go.jp/records/72144
4382f98a-7d4a-479e-b18d-51724226c3cb
Item type 会議発表用資料 / Presentation(1)
公開日 2017-01-30
タイトル
タイトル Alpha-radioimmunotherapy with At211-trastuzumab against peritoneal metastasis of HER2-overexpressing gastric cancer.
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_c94f
資源タイプ conference object
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 李, 惠子

× 李, 惠子

WEKO 710354

李, 惠子

Search repository
長谷川, 純崇

× 長谷川, 純崇

WEKO 710355

長谷川, 純崇

Search repository
李 惠子

× 李 惠子

WEKO 710356

en 李 惠子

Search repository
長谷川 純崇

× 長谷川 純崇

WEKO 710357

en 長谷川 純崇

Search repository
抄録
内容記述タイプ Abstract
内容記述 Peritoneal metastasis of gastric cancer (PMGC) has extremely poor prognosis, however, there is no effective therapeutics has been established. Trastuzumab, a humanized anti-HER2 monoclonal antibody, has been used for the treatment for HER2-overexpressed (HER2+) GC since about 20% of GC is reported as HER2+. Radioimmunotherapy (RIT), the internal radiotherapy using antibody as the carrier to deliver radioisotope (RI) to cancer specifically, has huge advantage in targeting metastatic cancer. Recently, alpha-RIT, using alpha emitting RI, is getting higher attention, because the high cell cytotoxicity and short range of alpha particle can prevent damages to untargeted tissues with effective cell killing effect. Astatine 211 (At211) is one of the useful alpha-RI.In this study, we investigated the cell cytotoxicity and therapeutic efficacy of RIT with At211-trastuzumab against HER2+ PMGC both in vitro and in a preclinical mouse model. We will discuss the possibility of alpha-RIT with At211-trastuzumab as a new effective therapeutic for HER2+ PMGC.
会議概要(会議名, 開催地, 会期, 主催者等)
内容記述タイプ Other
内容記述 International Symposium on Immune Diversity and Cancer Therapy Kobe 2017
発表年月日
日付 2017-01-27
日付タイプ Issued
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 19:43:16.767613
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3